MINNEAPOLIS, May 17 /PRNewswire-FirstCall/ -- VASAMED (BULLETIN BOARD: OPTL) announced that Terry Duesterhoeft joined the company as its new Vice President of Sales & Marketing as of January 2004.
Paulita LaPlante, president and chief executive officer, said, "In preparation for launching SensiLase(TM) PAD 3000, an improved version of our Skin Perfusion Pressure System, as well as adding new products, we needed an experienced sales and marketing officer with a strong background in vascular medicine. Terry has more than 15 years of experience in marketing, sales and business development most notably spent at GE's Medical and Ultrasound divisions during periods of rapid expansion. His time as Global Marketing Manager, General Imaging Leadership & Premium Segment at GE provides us with highly valued international experience as he helped to grow the ultrasound business from less than $50M to $700M in six years. Terry's most recent position as VP Marketing and Business Development for ZONARE, a compact ultrasound manufacturer, additionally provides us with valuable and recent insight regarding high tech start-up environments, price point management for emerging technology and key opinion leader contact. Terry is a significant asset to VASAMED at this critical juncture in our business. I am very proud to welcome him to our executive team."
"Joining the VASAMED team is a privilege," according to Terry Duesterhoeft. "The longevity of talent and experience of this group as a team coupled with the company's vision of fast, non-invasive assessment of hemodynamic health is a potent combination. With the aging population, rapid growth in diabetes worldwide and the spread of cardiovascular disease, VASAMED is expanding in the marketplace at precisely the right time and with the right products and vision."
VASAMED is a technology development company specializing in low-cost, non-invasive vascular diagnostic systems for non-invasive hemodynamic monitoring. Products developed by VASAMED include the CapnoProbe(TM) sensor system for the measurement of sublingual CO2. VASAMED licensed an application of CapnoProbe technology to Nellcor in 2001 which has positioned the product as an early warning signal of tissue hypoperfusion and possible organ failure. VASAMED manufactures and supplies LASERDOPP PV2000, a skin perfusion pressure and pulse volume waveform diagnostic for quantitative evaluation of small vessel disease in patients with chronic foot ulcers, diabetes and other peripheral arterial disease. Skin perfusion pressures are not affected by edema, anemia, medial calcification or certain other conditions that limit the usefulness of other measurement technologies.
For more information about VASAMED technology and services, see the company's web sites at http://www.opsi.com/ and at http://www.vasamedics.com/ . For more information about Nellcor(R) CapnoProbe(TM) Sublingual (SL) System, see http://www.nellcor.com/ .
CONTACT: Wes Peterson, CFO of VASAMED, +1-952-944-5857, ext. 542